Announcement • Oct 15
Optiscan Imaging Limited, Annual General Meeting, Nov 14, 2025 Optiscan Imaging Limited, Annual General Meeting, Nov 14, 2025. Location: 16 miles street, mulgrave victoria 3170 Australia New Risk • Sep 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Revenue is less than US$5m (AU$3.7m revenue, or US$2.4m). Market cap is less than US$100m (AU$88.8m market cap, or US$58.3m). Reported Earnings • Sep 01
Full year 2025 earnings released: AU$0.008 loss per share (vs AU$0.007 loss in FY 2024) Full year 2025 results: AU$0.008 loss per share (further deteriorated from AU$0.007 loss in FY 2024). Revenue: AU$3.72m (up 25% from FY 2024). Net loss: AU$6.31m (loss widened 4.1% from FY 2024). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Aug 27
Optiscan Imaging Limited has filed a Follow-on Equity Offering in the amount of AUD 17.750992 million. Optiscan Imaging Limited has filed a Follow-on Equity Offering in the amount of AUD 17.750992 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 208,835,201
Price\Range: AUD 0.085
Transaction Features: Rights Offering New Risk • May 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (AU$5.0m revenue, or US$3.2m). Market cap is less than US$100m (AU$104.4m market cap, or US$67.6m). Announcement • Apr 01
Optiscan Imaging Limited Promotes Darius Ooi as Chief Financial Officer Optiscan Imaging Limited announced a reorganisation of its executive team. Post this revamp, the Company will be better placed to both successfully deliver on its stated transformation, clinical and regulatory strategies, and develop a number of exciting products currently in the pipeline. The Company's Finance Manager, Mr. Darius Ooi, has been promoted to Chief Financial Officer, and has assumed responsibility of the Corporate team. Darius has been with the Company for nearly three years and has led the transformation of the Finance function to support the Company's global strategy with an expanding product portfolio. He is an experienced Chartered Accountant who has worked with a variety of businesses, ranging from small enterprises to large corporations, adeptly navigating the complexities of finance and business operations. In his previous role at a large multinational medical device company, Darius played a pivotal role in several transformation projects that significantly contributed to revenue growth and operational efficiency. At Optiscan, Darius has already built a track record for successfully delivering multiple finance-related initiatives and has been instrumental in developing long-term financial strategies aligned to the Company's transformation journey. All this while managing capital expenditure, managing risk and compliance responsibilities, and playing a key role in the Company's investor- and corporate relations-related tasks. Announcement • Mar 31
Optiscan Imaging Limited Announces Executive Changes Optiscan Imaging Limited announced a reorganisation of its executive team. Post this revamp, the Company will be better placed to both successfully deliver on its stated transformation, clinical and regulatory strategies, and develop a number of exciting products currently in the pipeline. Optiscan has recently completed a comprehensive review of its operations, sales and marketing functions, and clinical and regulatory strategy. A key outcome from this broad-ranging review process was an identified need for Optiscan to realign its Customer (Sales & Marketing), Clinical (Clinical & Regulatory), and Corporate (Finance, Info Technology, Investor Relations/Public Relations) teams in order to meet its stated objectives. To realise this realignment of key corporate responsibilities, the Company has taken steps to consolidate and refocus these functions internally to maintain agility, while building additional support and resources by engaging domain experts, consultants and advisors with deep experience in the US MedTech market. In an Australia-based appointment, Ms Belinda Williamson has been appointed to the position of Chief Commercial Officer. In this role, Belinda will lead Optiscan's Sales and Marketing team and steer the Company's efforts to realise the value of the Company's expanding catalogue of commercial opportunities. Belinda is a dynamic people leader with a proven track record of leading and managing teams that consistently deliver outstanding growth in sales revenue and market share within the global health care delivery and medical device industry. She was previously Group Sales Manager Medical and National Sales Manager (Surgical Division) at Olympus Medical, and Regional Sales Manager and Strategic Account Manager at Johnson & Johnson Medical. She earlier held sales and marketing roles at Guidant Corporation, Boston Scientific, Bard Australia and Zimmer Australia. Following the departure of Ms Nicole Williams and Mr. Ken Lock, Optiscan has appointed Ms Jessica Ward as its US-based Director of Clinical & Regulatory Affairs to manage the Company's burgeoning clinical and regulatory portfolios in Australia, Germany and the US, and lead the Clinical team. Her initial focus will be the successful execution of upcoming clinical trials for US FDA regulatory clearance of Optiscan's new imaging solutions for surgery and pathology. Jessica is a seasoned leader who has successfully driven global clinical and medical affairs initiatives for a number of renowned organisations, including the Stryker Corporation and Atrium Health. Most recently, she led clinical and medical affairs teams at Stryker Instruments, overseeing a wide range of global projects specialising in developing clinical evidence generation strategies to support global regulatory clearances across diverse medical specialties, including Orthopaedic, Neurosurgical, ENT, and Interventional Pain. The Company's US Business Development team for its life sciences product, ViewnVivo® has also undergone consolidation. This process has seen the departure of Mr. Tim Rowe, and the retention of Ms Shayra Leon who will assume responsibility for this product line in the US, as well as Optiscan's new veterinary product which is progressing through the product pipeline. Separately, Mr. Brendan Fafiani has decided to step down as Optiscan's Chief Operating Officer. He has worked closely with Optiscan's leadership team to ensure a smooth and structured transition. Announcement • Oct 08
Optiscan Imaging Limited, Annual General Meeting, Nov 21, 2024 Optiscan Imaging Limited, Annual General Meeting, Nov 21, 2024. New Risk • Sep 03
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: AU$142.0m (US$95.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$3.5m revenue, or US$2.4m). Market cap is less than US$100m (AU$142.0m market cap, or US$95.6m). Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.007 loss in FY 2023) Full year 2024 results: AU$0.007 loss per share (in line with FY 2023). Net loss: AU$6.06m (loss widened 39% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. New Risk • May 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Revenue is less than US$5m (AU$2.3m revenue, or US$1.6m). Market cap is less than US$100m (AU$87.7m market cap, or US$58.5m). Announcement • Oct 23
Optiscan Imaging Limited Appoints Brendan Fafiani to the Role of Chief Operating Officer, Effective 6 November 2023 Optiscan Imaging Limited announced the appointment of Brendan Fafiani to the role of Chief Operating Officer. Effective 6 November 2023, Brendan will assume responsibility for Optiscan's operations at its Melbourne headquarters, leading the development of the Company's operational planning and overseeing its commercialisation strategy encompassing sales and marketing, as well as managing personnel, and customer and development efforts. Optiscan CEO, Dr Camile Farah, will continue to focus on key investor relations, stakeholder engagement initiatives, and the US expansion plan. Brendan joins Optiscan from Cyban Pty Ltd, where, as the Chief Executive Officer he led the initialcommercialisation of a pioneering non-invasive Brain Oxygen and Intracranial Pressure monitor. Prior to this, as Vice President of Product and General Manager at Global Kinetics, Brendan led the product development of a novel Parkinson's disease monitor through regulatory clearance and launch into the US, Europe, and APAC. Prior to relocating to Australia, as Associate Director Operations within Merck KGaA's Medical Device Global Business Franchise, headquartered in Switzerland, he was responsible for the lifecycle management of a large portfolio of device and digital technologies. Brendan brings a wealth of expertise in the introduction of new technologies into existing treatment pathways, both in start-ups undergoing rapid growth and large multinational corporations, across neurodegenerative and cardiometabolic diseases, endocrinology and acquired brain injury fields. Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.007 loss in FY 2022) Full year 2023 results: AU$0.007 loss per share (in line with FY 2022). Revenue: AU$2.65m (up 18% from FY 2022). Net loss: AU$4.35m (loss widened 2.8% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Announcement • Aug 31
Optiscan Imaging Limited, Annual General Meeting, Nov 23, 2023 Optiscan Imaging Limited, Annual General Meeting, Nov 23, 2023. New Risk • Aug 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.9m free cash flow). Earnings have declined by 17% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (35% increase in shares outstanding). Revenue is less than US$5m (AU$1.9m revenue, or US$1.2m). Market cap is less than US$100m (AU$61.8m market cap, or US$40.1m). New Risk • Jul 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.9m free cash flow). Earnings have declined by 17% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (AU$1.9m revenue, or US$1.3m). Market cap is less than US$100m (AU$61.1m market cap, or US$42.1m). Reported Earnings • Mar 04
First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022) First half 2023 results: AU$0.004 loss per share (further deteriorated from AU$0.003 loss in 1H 2022). Revenue: AU$1.07m (down 25% from 1H 2022). Net loss: AU$2.37m (loss widened 23% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 52% per year, which means it is well ahead of earnings. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Non-Executive Director Ron Song is the most experienced director on the board, commencing their role in 2021. Independent Non-Executive Director Karen Borg was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Sep 01
Full year 2022 earnings released: AU$0.007 loss per share (vs AU$0.004 loss in FY 2021) Full year 2022 results: AU$0.007 loss per share (down from AU$0.004 loss in FY 2021). Revenue: AU$2.28m (up 1.4% from FY 2021). Net loss: AU$4.23m (loss widened 99% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings. Announcement • Sep 01
Optiscan Imaging Limited, Annual General Meeting, Nov 24, 2022 Optiscan Imaging Limited, Annual General Meeting, Nov 24, 2022. Announcement • Aug 22
Optiscan Submits FDA 510(k) Application for InVivage Device Optiscan Imaging Limited announced submission of its FDA (United States Food and Drug Administration) Pre-Market Notification (510(k)) application for the InVivage® device intended for oral tissue imaging. InVivage® is a next generation, non-invasive, instantaneous form of oral imaging, targeting the severe health consequences of late-stage diagnosis of oral cancers and precancerous lesions. The technology platform enables real-time, non-destructive, 3D, in-vivo imaging at the sub-cellular level which aims to provide physicians, surgeons and pathologists with high resolution microscopic images intraoperatively that can be used to assist with diagnosis and treatment of various oral pathologies. Recent Insider Transactions • Jul 29
Insider recently bought AU$1.9m worth of stock On the 27th of July, Robert Peters bought around 20m shares on-market at roughly AU$0.10 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$4.6m more in shares than they have sold in the last 12 months. Announcement • Jun 14
Optiscan Imaging Limited Appointment of Sean Gardiner as Non-Executive Director The Board of Optiscan Imaging Limited announced the appointment of Mr. Sean Gardiner as a non-executive director of the Company. Pursuant to clause 7.1 of the Subscription Agreement between Optiscan and Orchid Capital Investments Pte. Ltd. dated 21 September 2020, Orchid Capital Investments Pte. Ltd. nominates Mr. Sean Gardiner as its new "Subscriber Nominee" (as defined in the Subscription Agreement) to Optiscan's Board of Directors. Sean is a Managing Director and Head of Private Investments at the Clermont Group. Prior to joining Clermont, Sean worked at Morgan Stanley, where he spent 20 years in equity research across three locations and in seven different roles. In 2000, he joined the London office covering European Technology and Conglomerate stocks before, in 2005, moving to lead the EEMEA Telecom Services team. In early 2008, Sean transferred to Dubai to setup and manage the MENA Equity Research team. Sean relocated to Singapore in 2010 to oversee and manage the broader Asian research product as well as roll out ASEAN Real Estate coverage. In 2016, he was promoted to Head of ASEAN Research and ASEAN Equity Strategist. Prior to Morgan Stanley, Sean served his Chartered Accountancy articles in South Africa and he has a B.Com (PGDA) from the University of Cape Town. Board Change • Apr 27
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Non-Executive Director Ron Song is the most experienced director on the board, commencing their role in 2021. Independent Non-Executive Director Karen Borg was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Recent Insider Transactions • Apr 14
Insider recently bought AU$1.2m worth of stock On the 13th of April, Robert Peters bought around 8m shares on-market at roughly AU$0.15 per share. In the last 3 months, they made an even bigger purchase worth AU$1.4m. Insiders have collectively bought AU$7.7m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Mar 18
Insider recently bought AU$1.4m worth of stock On the 15th of March, Robert Peters bought around 9m shares on-market at roughly AU$0.17 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$6.4m more in shares than they have sold in the last 12 months. Reported Earnings • Sep 01
Full year 2021 earnings released: AU$0.004 loss per share (vs AU$0.004 loss in FY 2020) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$2.54m (up 34% from FY 2020). Net loss: AU$2.13m (loss widened 21% from FY 2020). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth. Executive Departure • Aug 05
Non-Executive Director Graeme Mutton has left the company On the 30th of July, Graeme Mutton's tenure as Non-Executive Director ended after 3.3 years in the role. As of March 2021, Graeme still personally held 10.96m shares (AU$219k worth at the time). Graeme is the only executive to leave the company over the last 12 months. Announcement • Jun 01
Optiscan Imaging Limited Announces Update on seeking United States FDA approval & market entry Optiscan Imaging Limited provided an update on progress relating to its preparation for lodgment of its application for United States Food and Drug Administration (FDA) 510(k) clearance ("510(k) Application") to market its InVivage device for Oral Cancer Screening and/or Surgery in the United States. InVivage is a next generation, non-invasive, instantaneous form of oral cancer screening targeting the severe health consequences of late stage diagnosis of oral cancer. The Company has completed multiple internal and external validation requirements for the 510(k) Application at its premises and contract testing facilities in the United States ("Requirements"). During the course of meeting
these Requirements, the Company has made further software and hardware improvements and undertaken additional testing and improvements in the functionality, useability and robustness of the InVivage device. Is New 90 Day High Low • Feb 22
New 90-day high: AU$0.23 The company is up 119% from its price of AU$0.10 on 24 November 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 1.0% over the same period. Announcement • Feb 10
Optiscan Imaging Limited Announces Appointment of Ron Song as New Non-Executive Director The Board of Optiscan Imaging Limited announced the appointment of Mr. Ron Song as a non-executive director of the Company. Ron brings a wealth of experience in management, sales and marketing within diverse businesses in both Australia and Singapore. Announcement • Feb 08
Optiscan Imaging Limited Announces Commencement of Stage Three of its Breast Cancer Study in Melbourne Optiscan Imaging Limited announced the commencement of stage three of its breast cancer study in Melbourne. The study will be conducted by leading breast cancer surgeon, Professor Ian Mann, and will involve 20 breast cancer patients at Royal Melbourne Hospital, Frances Perry House and Epworth Hospital using Optiscan`s FIVE2/Viewnvivo endomicroscope. Professor Mann is the Director of Breast Cancer Services for the Royal Melbourne Hospital and Royal Women's Hospital, and a Professor of Surgery at The University of Melbourne. The Optiscan endomicroscope enables real-time, 3D, `in vivo' imaging of human tissue at the cellular level. It provides instant `virtual biopsies' for cancer screening enabling faster diagnosis and treatment. The hand- held instrument allows surgeons and pathologists to instantly view tissue at 1,000 times magnification enabling clinicians, surgeons and pathologists to identify cancerous tissue on the surface of a specimen in real time, reducing or eliminating the need to have specimens sent to a laboratory for processing which can take two to three days. Announcement • Jan 13
OptiScan Imaging Limited Receives Orders from Carl Zeiss Meditec AG OptiScan Imaging Limited advised that it has received orders from Carl Zeiss Meditec AG pursuant to its Co-operation Agreement for approximately AUD 350,000. Announcement • Oct 10
Optiscan Imaging Limited Announces US FDA Regulatory Approval Update Optiscan Imaging Limited announced that it has received written feedback from the Center for Devices and Radiological Health (CDRH) of the FDA in response to specific questions raised by the Company following its meeting with the FDA in January 2020 and subsequent written submissions made in late June 2020. Following this feedback, Optiscan will continue to prepare its submission for 510(k) clearance to market the InVivageTM device for legal sale in the United States in Oral Cancer Screening and/or Surgery. In particular, Optiscan is pleased with the affirmative responses from the FDA regarding the proposed Product Code, Primary Predicate Device and use of the CONVIVO® device as a Reference Device. The next step is the clinical study regarding the effectiveness (dosing and time to imaging) of the
use of a topically applied imaging agent for use in conjunction with the InVivageTM device will be
conducted with the Melbourne Dental School and will take place simultaneously with the third party validation and verification testing which is required to be completed for the 510(k) submission. This testing will commence in the current quarter. Announcement • Sep 22
Optiscan Imaging Limited announced that it expects to receive AUD 9.813499 million in funding from Orchid Fund Pte. Limited and other investors Optiscan Imaging Limited (ASX:OIL) announced a private placement of 118,951,500 shares at a price of AUD 0.0825 per share for gross proceeds of up to AUD 9,813,498.75 on September 21, 2020. The company has entered into a binding subscription agreement with Orchid Fund Pte. Limited. For every four shares, one free attaching option will be issued, exercisable at AUD 0.15 per option, each option entitling the holder to subscribe for one fully paid ordinary share and with an expiry date of 30 months from the date of issue. Orchid Fund Pte. Limited will act as lead investor and has applied for subscription of approximately 89,485,000 shares for gross proceeds of approximately AUD 7,382,513. The investor, Orchid Fund Pte. Limited, will have the right (but not the obligation) to appoint one non-executive director to the board of the company pursuant to the agreement, subject to maintaining at least a 10% interest in the company. The issue of the options will be subject to shareholder approval at the upcoming annual general meeting on November 26, 2020. The transaction is expected to close on September 28, 2020. Announcement • Sep 09
Optiscan Imaging Limited Auditor Raises 'Going Concern' Doubt Optiscan Imaging Limited filed its Annual on Aug 31, 2020 for the period ending Jun 30, 2020. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Announcement • Jul 25
Optiscan Image Ltd Ordinary Shares to Be Deleted from Other OTC Optiscan Image Ltd. (Liquidation)'s Ordinary Shares will be deleted from other OTC effective from June 30, 2020 due to Inactive Security. 